ODN 1585, a TLR9 agonist, is reported to prolong pancreatic islet allograft survival and enhance insulin production by enhancing the expansion of the natural killer cell subsets producing IL-22 in the liver in T1D mice (35). This evidence concerns the gene IL22 and type 1 diabetes mellitus.